metric measurements were carried out. Results -Sputum elastase activity decreased at 12 weeks and was maintained at 52 weeks when a decline in total plasma elastase was also observed. Although, as expected, there was a correlation between plasma levels of total elastase and neutrophil elastase/alPI complex, the decrease in the levels of the complex at 52 weeks did not reach statistical significance. Conclusions -This study indicates that prolonged daily administration of rhDNase results in a reduction in elastase load in patients with cystic fibrosis.
(Thorax 1996;51:619-623) Keywords : cystic fibrosis, recombinant DNase, neutrophil elastase.
Airway obstruction caused by the accumulation of tenacious viscid secretions in the bronchi is the hallmark of respiratory disease in cystic fibrosis. DNA derived from the disintegration of inflammatory cells, particularly neutrophils, is a major contributor to the viscosity of airway secretions and is present in very high concentrations in the sputum of patients with cystic fibrosis.' As early as the 1950s it was shown that DNase isolated from bovine pancreas reduced sputum viscosity both in vitro and in vivo, suggesting that aerosolised administration of DNase might alleviate airway obstruction in patients with cystic fibrosis. 23 Following reports of severe adverse respiratory reactions such as bronchospasm, however, treatment with bovine DNase was largely abandoned.4 Recently, the successful cloning and production of recombinant human DNase (rhDNase) has revived interest in DNase therapy. Sputum samples were maintained at room temperature and processed within one hour of collection to prevent neutrophil degranulation following sampling. A volume of0 07M sodium phosphate buffer (pH 6-0, containing 0-5M NaCl and 50,ug/ml dithiothreitol) equivalent to five times the sputum weight was added and the sample gently agitated (manually) until a uniform suspension was obtained. This suspension was then divided into two equal aliquots. To one aliquot the serine protease inhibitors, phenylmethylsulphonyl fluoride (PMSF) and di-isopropyl fluorophosphate (DIPF) , and the metalloproteinase inhibitors, ethylenediamine tetraacetic acid (EDTA) and phenanthroline (PA), at a final concentration of 10 mM, were added to prevent proteolysis following sampling. The second aliquot was retained without the addition of inhibitors to enable assessment of enzyme activity. All aliquots were centrifuged at 30000 g for 30 minutes and the resulting supernatants were stored at -70°C prior to analysis. To fully evaluate elastase load, sputum samples were analysed for elastase activity and total immunoreactive elastase. Levels of the neutrophil chemoattractant IL-8 were also assessed.
Sodium citrate was used as anticoagulant for the collection of blood samples. Plasma was collected by centrifugation at 350 g for 10 minutes and stored at -70°C until assayed. As elastase is rapidly bound and inactivated by inhibitors when it enters the bloodstream, it was assessed in plasma samples by measurement of total immunoreactive elastase and elastase complexed to ox1PI. Plasma IL-8 levels were also assessed.
Assessment of neutrophil elastase activity Sputum samples that did not contain protease inhibitors were assayed for elastase activity using the chromogenic peptide substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (Sigma, Poole, UK) at a concentration of 4-2 mM.25 Using an extinction coefficient of 8800/l/mol/cm, molar concentrations of peptide hydrolysed were determined and enzyme units, defined as the release of 1 M p-nitroanilide/min/ml sputum, were calculated. Assessment of total immunoreactive neutrophil elastase An indirect ELISA for the measurement of neutrophil elastase was used to assay total elastase levels in sputum and plasma samples. Briefly, a 96-well microtitre plate was coated overnight with neutrophil elastase in sodium carbonate buffer, pH 9-6, containing 1-75 mM PMSF. The plate was washed with phosphate buffered saline (PBS)/0-1% Tween and nonspecific binding sites were blocked with PBS/ 1 % bovine serum albumin for one hour at 37°C. Standards significant. Values for plasma and sputum measurements and pulmonary function data are presented as mean (SE).
Results

CLINICAL RESPONSE TO RHDNASE
All 15 patients recruited to the study were evaluated at 11-12 weeks. Eleven completed the full 52 week study. One man aged 24 died during the study period and a further three (two women and one man aged 19-23 years) failed to return as scheduled for the 52 week visit. With the exception of the patient who died, information on the number of courses of intravenous antibiotics administered was available on all patients over the full duration of the study.
Little overall change in pulmonary function was observed either at 12 weeks or 52 weeks following initiation of rhDNase therapy (table 1), although considerable individual variation was observed. At 12 weeks seven (47%) patients showed an increase in forced vital capacity (FVC) of 5% or more above baseline levels. Similar increases (>5% above baseline) in forced expiratory volume in one second (FEVI) were observed in five of these patients.
However, in four (27%) patients a fall of 5% in both FVC and FEV1 was observed. By 52 weeks an improvement in FEV, was maintained in only 27% of patients studied.
During the course of the study only two patients remained free of infective exacerbations. The remaining 12 patients required intravenous antibiotic therapy 1-8 times (mean number of infective episodes = 2-7 (0-6)).
ALTERATIONS IN ELASTASE LOAD FOLLOWING RHDNASE THERAPY
There was a significant decrease in sputum elastase activity (p<0 05) at 12 weeks following initiation of rhDNase therapy (table 2) . However, there was no corresponding change in total (immunogenic) sputum or plasma elastase levels or in plasma levels of the elastase/ot,PI complex at this time. The reduction in sputum elastase activity observed at 12 weeks was maintained at 52 weeks (table 2), at which time a significant reduction in total plasma elastase (p<0005) was also observed (figure). Although, as expected, there was a significant correlation between plasma levels of total elastase and elastase/ot1PI complex (r= 0-65, p<OOl), the decrease in elastase/ot1PI complex levels observed at 52 weeks did not reach statistical significance. No relationship between alterations in elastase levels and change in lung function was observed (p = 0 057).
IL-8 LEVELS
Nanogram quantities of IL-8 were readily detectable in baseline sputum samples from all patients. Nebulised rhDNase treatment for either 12 patients who developed respiratory tract infections were excluded from the study. In the current study a decrease in elastase load was observed even though most of the patients experienced at least one infective exacerbation over the 52 week period. These data suggest that concerns over the possible deleterious effect of long term rhDNase treatment on elastase load in cystic fibrosis are largely unfounded. Several studies have implicated IL-8 as a major mediator of neutrophil influx to the lung in inflammatory diseases.2728 Khan and coworkers have recently reported the presence of high levels of IL-8 in the lungs of infants with cystic fibrosis in the absence of colonisation with common cystic fibrosis-related pathogens.'2 These authors suggest that expression of IL-8 by alveolar macrophages may be fundamental to the neutrophil dominated inflammatory response in the lungs of patients with cystic fibrosis. In the current study treatment with rhDNase was ineffective in reducing the high levels of IL-8 observed in sputum samples, suggesting that clearance of mucus from the airways may have little effect in reducing underlying neutrophil chemotaxis.
Although the main purpose of this study was to assess alterations in elastase load during rhDNase therapy, the lack of improvement in pulmonary function deserves comment. Both short term (1-2 weeks) and long term (up to two years) clinical trials report significant improvement over baseline values in both FEV, and FVC in patients treated with rhDNase. While the extent of initial improvement observed within days of commencement of therapy (10-15%) is not maintained, sustained increases of 4-7% over baseline are observed with daily administration of rhDNase over a two year period. 29 In all studies, however, significant individual variation in response is observed. In the largest study carried out to date Fuchs et al indicate that 6-7% of treated patients actually experienced a decline in FEVy of more than 10%. 8 Davis has suggested that a significant improvement in FEVy will be observed in less than 30% of patients, a figure similar to the 27% of patients in our study who displayed a sustained improvement in FEVL over the 52 week study period. 30 Other recent studies report results consistent with those observed here, suggesting that only a proportion of patients may derive sustained benefit in pulmonary function from DNase therapy.3" In summary, this study indicates that prolonged daily administration of rhDNase results in decreases in sputum elastase activity and in plasma levels of total neutrophil elastase, thus serving to reduce, rather than increase, the elastase load in patients with cystic fibrosis.
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